Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $46.43 and traded as high as $55.72. Xenon Pharmaceuticals shares last traded at $54.48, with a volume of 966,676 shares trading hands.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Wolfe Research assumed coverage on Xenon Pharmaceuticals in a research report on Monday, February 23rd. They issued an “outperform” rating and a $60.00 target price for the company. Deutsche Bank Aktiengesellschaft upped their price objective on Xenon Pharmaceuticals from $56.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, March 10th. Needham & Company LLC lifted their target price on Xenon Pharmaceuticals from $58.00 to $80.00 and gave the stock a “buy” rating in a report on Monday, March 9th. Wedbush reduced their price objective on shares of Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating for the company in a research report on Monday, March 16th. Finally, Stifel Nicolaus set a $66.00 price objective on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 10th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Xenon Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $71.88.

Xenon Pharmaceuticals Trading Down 1.9%

The firm’s 50-day simple moving average is $46.43 and its two-hundred day simple moving average is $43.03. The stock has a market capitalization of $4.53 billion, a PE ratio of -12.50 and a beta of 0.91.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same quarter last year, the firm posted ($0.84) earnings per share. As a group, research analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Insider Buying and Selling at Xenon Pharmaceuticals

In other news, CEO Ian Mortimer sold 270,000 shares of the business’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $60.33, for a total transaction of $16,289,100.00. Following the transaction, the chief executive officer directly owned 6,000 shares in the company, valued at $361,980. The trade was a 97.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Christopher John Kenney sold 2,771 shares of the company’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total transaction of $166,564.81. Following the completion of the transaction, the insider directly owned 4,729 shares in the company, valued at $284,260.19. This trade represents a 36.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 336,707 shares of company stock valued at $19,622,565 in the last 90 days. 4.07% of the stock is currently owned by corporate insiders.

Institutional Trading of Xenon Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Holocene Advisors LP bought a new position in shares of Xenon Pharmaceuticals during the 2nd quarter valued at $56,637,000. Wellington Management Group LLP lifted its position in shares of Xenon Pharmaceuticals by 66.0% in the third quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock worth $144,936,000 after buying an additional 1,435,096 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Xenon Pharmaceuticals by 1,294.2% in the second quarter. Geode Capital Management LLC now owns 970,343 shares of the biopharmaceutical company’s stock worth $30,369,000 after buying an additional 900,746 shares during the last quarter. Braidwell LP boosted its stake in shares of Xenon Pharmaceuticals by 33.0% during the 2nd quarter. Braidwell LP now owns 3,605,029 shares of the biopharmaceutical company’s stock worth $112,837,000 after acquiring an additional 895,154 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Xenon Pharmaceuticals by 1,968.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 862,300 shares of the biopharmaceutical company’s stock worth $38,650,000 after acquiring an additional 820,608 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.